Curai
+18%
est. 2Y upside i
Rank
#1640
Sector
Virtual Primary Care / AI HealthTech
Est. Liquidity
~3Y
Data Quality
Data: LowCurai Health offers a compelling AI-driven virtual care platform with $34.6M revenue and 75% gross margins.
Last updated: July 19, 2026
If an IPO window opens and Curai achieves category leadership, exit multiple expands to 6x on $55M revenue, implying $330M exit. After 20% dilution, upside is 80%.
Exit multiple converges to ~4x, in line with public health-tech comps, on $55M revenue = $220M exit. After 20% dilution, upside is 26.7%.
Multiple compresses to 2.5x due to competition and lack of profitability, giving $137.5M exit. After 20% dilution, upside is -28.3%.
Preference Stack Risk
severeFunding Intensity
38%Total funding $57M against estimated entry valuation $150M gives 38% preference overhang, meaning common stock faces significant downside risk in a lower exit.
Dilution Risk
highWith no recent funding and potential cash needs, a new round in 24 months likely dilutes existing equity by 20% or more.
Secondary Liquidity
noneNo secondary market activity detected; employees likely have no early liquidity options.
Clinical — 6 roles
AI — 1 role
- Staff AI Engineer · Remote
Last updated: February 22, 2026
Questions to Ask at the Interview
Strategic questions based on Curai's data — designed to show you've done your homework.
- 1
“How does Curai's AI platform improve diagnosis accuracy and differentiate from incumbents like Teladoc?”
- 2
“What is the company's path to profitability and how does the subscription model drive recurring revenue?”
- 3
“Given the 2020 Series B, what is the current cap table and how might future funding rounds affect employee equity?”
Community
Valuation Sentiment
Our model estimates +18% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.